Suppression of Collagen‐Induced Arthritis by Combination Cyclosporin a and Methotrexate Therapy

Arthritis & Rheumatism

Volumn 34, Issue 10, 1991, Pages 1282-1288

  Brahn, Ernest ^a   Peacock, Derek J ^a   Banquerigo, Mona Lisa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; CYCLOSPORIN A; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG COMBINATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PHARMACOLOGY; PRIORITY JOURNAL; RADIOLOGY; RAT;

ANIMAL; ANTIBODIES; ARTHRITIS; COLLAGEN; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HYPERSENSITIVITY, DELAYED; METHOTREXATE; RATS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026058617     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780341012     Document Type: Article

References (38)

1. Autoimmunity to type II collagen: an experimental model of arthritis
2. Role of T lymphocytes in collagen II induced arthritis in rats
3. Effect of antithymocyte serum on collagen arthritis in rats: evidence that T cells are involved in its pathogenesis
4. Experimental synovitis induced by collagen‐specific T cell lines
5. Paradoxical effects of cyclosporin A on collagen arthritis in rats
6. The anti‐arthritic and immunosuppressive effects of cyclosporin on arthritis induced in the rat by type II collagen
7. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double‐blind study
8. A controlled two center trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
9. Efficacy of lowdose methotrexate in rheumatoid arthritis
10. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial
11. Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double‐blind, multicenter study
12. Cyclosporin in rheumatoid arthritis: a double‐blind, placebo controlled study in 52 patients
13. Cyclosporin A in severe, treatmentrefractory rheumatoid arthritis: a randomized study
14. Controlled trial of hydroxychloroquine and D‐penicillamine singly and in combination in the treatment of rheumatoid arthritis
15. Combined gold and hydroxychloroquine in rheumatoid arthritis
16. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine and hydroxychloroquine: a follow up study
17. Methotrexate and cyclosporin compared with cyclosporin alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
18. Antigen‐specific suppression of type II collagen‐induced arthritis by collagen‐coupled spleen cells
19. Augmentation of collagen arthritis by synthetic analogues of retinoic acid
20. Gold does not alter the arthritic, humoral, or cellular responses in rats with type II collagen‐induced arthritis
21. Antigen‐specific suppression of collagen arthritis by adoptive transfer of spleen cells
22. Attenuation of an adjuvant arthritis by type II collagen
23. Effect of cyclosporin A on T cell function in vitro: the mechanism of suppression of T cell proliferation depends on the nature of the T cell stimulus as well as the differentiation state of the responding T cell
24. Effect of cyclosporin A on human lymphocyte responses in vitro
25. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2
26. Cyclosporin A inhibits T cell growth factor gene expression at the level of mRNA transcription
27. Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A
28. Cyclosporin A inhibits antigen and lectin induced but not constitutive production of interleukin 3
29. Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjögren's syndrome
30. Effects of methotrexate therapy on 5‐lipoxygenase pathway metabolism of arachidonic acid in rheumatoid arthritis (abstract)
31. A novel antiinflammatory action of methotrexate (MTX): MTX increases adenosine release from connective tissue cells and thereby inhibits neutrophil (PMN) function (abstract)
32. Effects of methotrexate on in vitro immune activity of lymphocytes from patients with rheumatoid arthritis (abstract)
33. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients
34. Models of arthritis and search for antiarthritic drugs
35. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis (abstract)
36. Radiological assessment of disease progression in rheumatoid arthritis patients from the randomized clinical trial of methotrexate, oral gold or combination (abstract)
37. Low dose cyclosporin versus placebo in patients with rheumatoid arthritis
38. Liver biopsies from psoriatics related to methotrexate therapy: findings in post‐methotrexate liver biopsies from 160 psoriatics